DRAIGON is at the forefront of developing creative solutions to fight AMR
The project goal is to create an innovative in vitro diagnostic device (IVD) to predict antimicrobial resistance in real-time.
top of page
Help us make a
difference sooner...
The Draigon Consortium proposes to validate and demonstrate the clinical efficacy of
a novel diagnostic test focusing on blood and periprosthetic joint infections at five hospitals in the Netherlands, Austria, Albania and the United States.
The DRAIGON Consortium plans to demonstrate performance for two critical prototype infections, namely bloodstream infections (BSI) and periprosthetic joint infections (PJI).
This diagnostic test will be easy to implement and may also function as an early detection system to prevent cross-border spread of pathogens.
To guide the implementation of the tools developed through DRAIGON, an extensive health technology assessment (HTA) will be performed.
This assessment will consider:
-
Health-economic implications
-
Patient outcomes
-
Social issues
Check the latest news:
Connect on LinkedIn: Join our professional network to connect with like-minded individuals, participate in discussions, and stay abreast of industry trends.
Follow us on X: Connect with us on X for regular updates, insightful articles, and opportunities to engage with our community.
bottom of page